Protagonist Therapeutics posts $162.8 million Q2 profit as rusfertide awaits FDA ruling

A milestone payment from Takeda and the first full quarter of ICOTYDE commercial sales moved Protagonist Therapeutics ($PTGX) into the black in Q2 2026, with profit at $162.8 million compared with a $34.8 million loss in the same period a year earlier. The next confirmable event is rusfertide's PDUFA goal date in August, when the FDA is scheduled to rule on the injectable's new drug application for polycythemia vera.

The numbers

License and collaboration revenue came in at $213.5 million for the quarter. Of that, $192.4 million traces to proportional recognition of Takeda's $200 million opt-out payment made in April, a single deal event rather than a commercial book building on itself. A year earlier, that same revenue line was $5.5 million. Cash and marketable securities stood at $849.5 million at quarter end, and earnings worked out to $2.29 per diluted share.

ICOTYDE, an oral psoriasis treatment, received FDA approval on March 18 for moderate-to-severe plaque psoriasis in patients 12 and older weighing at least 40 kilograms, triggering a $50 million milestone payment. Protagonist describes the drug as the first and only FDA-approved targeted oral peptide for the condition. Under the agreement with Johnson & Johnson, as much as $580 million in additional milestones remains available, plus royalties the company says average around 7.25 percent at $4 billion in annual sales.

Rusfertide's commercial future belongs to Takeda following the opt-out. Two payments remain outstanding: $200 million and a $75 million approval milestone. Royalties on the drug can reach 29 percent of sales above $1.5 billion.

The setup

Most of Q2's revenue reflects a single deal event, not repeatable product throughput. Management expects R&D costs to rise significantly in the second half of 2026 against the first half, driven by manufacturing investments, added headcount, and a new Phase 2b psoriasis program for PN-881, an oral IL-17 antagonist. A Phase 1 study for PN-477sc, an injectable obesity peptide, also just began. General and administrative costs are climbing on stock-based compensation. Short interest sits at 13.99 percent of the float. The stock's forward price-to-earnings ratio was 36.90 as of September 4, and hedge fund ownership edged from 42 to 43 funds last quarter.

Rusfertide's August PDUFA date is the tape's next hard event. Approval would trigger the $75 million milestone and open the royalty clock with Takeda.